Glurest PM 1 Tablet is a combination oral antidiabetic medication containing Glimepiride (1 mg), Metformin (500 mg), and Pioglitazone (15 mg), indicated for the management of type 2 diabetes mellitus. This formulation acts through complementary mechanisms to improve glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby lowering fasting and postprandial blood glucose levels. Pioglitazone, a thiazolidinedione, enhances insulin sensitivity in adipose tissue, muscle, and the liver by activating peroxisome proliferator-activated receptor gamma (PPAR-γ). The combined action of these agents provides effective control of hyperglycemia in patients inadequately managed by monotherapy or dual therapy. Glurest PM 1 Tablet is typically prescribed alongside diet and exercise modifications. Caution is advised in patients with renal or hepatic impairment, heart failure, or a history of lactic acidosis. Common adverse effects may include gastrointestinal disturbances, hypoglycemia, weight gain, and edema. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. This combination therapy should be used under medical supervision to optimize therapeutic outcomes and minimize potential risks.